Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine (PLACID)
The objective is to describe and quantify levels of platelet reactivity in three different cohorts of patients taking thienopyridine: patients who report nuisance bleeding, patients who report alarming bleeding, and patients who report no nuisance or alarming bleeding. The investigators hypothesize that patients with nuisance or alarming bleeding events on maintenance thienopyridine therapy will have lower levels of platelet reactivity than patients without nuisance or alarming bleeding on thienopyridine therapy.
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine|
- platelet reactivity [ Time Frame: post percutaneous coronary intervention (PCI) while still on clopidogrel ] [ Designated as safety issue: No ]Level of platelet reactivity as assessed with the Chrono-Log Lumi-Aggregometer, which measures levels of light transmittance after stimulation with ADP to estimate levels of platelet aggregation.
- Platelet reactivity [ Time Frame: post PCI while still on clopidogrel ] [ Designated as safety issue: No ]
- Platelet reactivity, as measured with the VerifyNow P2Y12 assay, expressed as platelet reactivity units (PRUs)
- Platelet reactivity, as assessed with the Vasodilator Stimulated Phosphoprotein (VASP) assay, which measures percentage platelet reactivity inhibition by flow cytometry of the VASP-P protein.
- Aspirin resistance, as assessed with the VerifyNow aspirin resistance assay, which measures aspirin resistance (ARUs).
|Study Start Date:||April 2010|
|Study Completion Date:||July 2011|
|Primary Completion Date:||June 2011 (Final data collection date for primary outcome measure)|
|United States, District of Columbia|
|Washington Hospital Center|
|Washington, District of Columbia, United States, 20010|
|Principal Investigator:||Michael Gaglia, MD||Cardiovascular Research Institute|